Moxifloxacin-induced tinnitus in an older adult.

Abstract

An increased risk of bacterial resistance toward fluoroquinolones and the increased risk of disabling and serious adverse effects prompted the US Food and Drug Administration to recommend limiting fluoroquinolone use to the treatment of community-acquired pneumonia, skin and skin-structure infections, bacterial sinusitis, plague, chronic bronchitis exacerbations, and complicated intra-abdominal infections. We report a case of moxifloxacin-induced tinnitus in an older adult prescribed oral moxifloxacin 400 mg for 5 days for the treatment of acute diverticulitis, due to allergies to nonfluoroquinolone preferred agents. A thorough literature review provided few other reported incidents of this rare and serious adverse event.

• Authors: Amber Onoh, Sunny A Linnebur, Danielle R Fixen
• Journal: Therapeutic advances in drug safety (Ther Adv Drug Saf) Vol. 9 Issue 4 Pg. 219-221 (Apr 2018) ISSN: 2042-0986 [Print] England
• PMID: 29623187 (Publication Type: Case Reports)